1 Saraux A, Pers JO, Devauchelle-Pensec V. Treatment of primary Sjogren syndrome. Nat Rev Rheumatol. 2016;12(8):456–71.
2 Ferro F, et al. One year in review 2016: Sjogren’s syndrome. Clin Exp Rheumatol. 2016;34(2):161–71.
3 Fox RI, Fox CM. Sjogren Syndrome: Why Do Clinical Trials Fail? Rheum Dis Clin North Am. 2016;42(3):519–30.
4 Vivino FB, et al. New Treatment Guidelines for Sjogren’s Disease. Rheum Dis Clin North Am. 2016;42(3):531–51.
5 Callaghan R, et al. Direct healthcare costs and predictors of costs in patients with primary Sjogren’s syndrome. Rheumatology (Oxford). 2007;46(1):105–11.
6 Barone F, Colafrancesco S. Sjogren’s syndrome: from pathogenesis to novel therapeutic targets. Clin Exp Rheumatol. 2016;34(4 Suppl 98):58–62.
7 Nakamura H, Kawakami A. What is the evidence for Sjogren’s syndrome being triggered by viral infection? Subplot: infections that cause clinical features of Sjogren’s syndrome. Curr Opin Rheumatol. 2016;28(4):390–7.
8 Ambrosi A, Wahren-Herlenius M. Update on the immunobiology of Sjogren’s syndrome. Curr Opin Rheumatol. 2015;27(5):468–75.
9 Nocturne G, Mariette X. Advances in understanding the pathogenesis of primary Sjogren’s syndrome. Nat Rev Rheumatol. 2013;9(9):544–56.
10 Reksten TR, Lessard CJ, Sivils KL. Genetics in Sjogren Syndrome. Rheum Dis Clin North Am. 2016;42(3):435–47.
11 Brito-Zeron P, et al. Treating the Underlying Pathophysiology of Primary Sjogren Syndrome: Recent Advances and Future Prospects. Drugs. 2016;76(17):1601–23.
12 Rischmueller M, Tieu J, Lester S. Primary Sjogren’s syndrome. Best Pract Res Clin Rheumatol. 2016;30(1):189–220.
13 Thompson N, et al. Exploring BAFF: its expression, receptors and contribution to the immunopathogenesis of Sjogren’s syndrome. Rheumatology (Oxford). 2016;55(9):1548–55.
14 Schiffman RM, et al. Utility assessment among patients with dry eye disease. Ophthalmology. 2003;110(7):1412–9.
15 Brito-Zeron P, Ramos-Casals M, and E.-S.t.f. group. Advances in the understanding and treatment of systemic complications in Sjogren’s syndrome. Curr Opin Rheumatol. 2014;26(5):520–7.
16 Ramos-Casals M, et al. Characterization of systemic disease in primary Sjogren’s syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. Rheumatology (Oxford). 2015;54(12):2230–8.
17 Fisher BA, et al. A review of salivary gland histopathology in primary Sjogren’s syndrome with a focus on its potential as a clinical trials biomarker. Ann Rheum Dis. 2015;74(9):1645–50.
18 Fayyaz A, Kurien BT, Scofield RH. Autoantibodies in Sjogren’s Syndrome. Rheum Dis Clin North Am. 2016;42(3):419–34.
19 Seror R, et al. European League Against Rheumatism Sjogren’s Syndrome Disease Activity Index and European League Against Rheumatism Sjogren’s Syndrome Patient-Reported Index: a complete picture of primary Sjogren’s syndrome patients. Arthritis Care Res (Hoboken). 2013;65(8):1358–64.
20 Seror R, et al. Validation of EULAR primary Sjogren’s syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Ann Rheum Dis. 2015;74(5):859–66.
21 Theander E, et al. Prediction of Sjogren’s Syndrome Years Before Diagnosis and Identification of Patients With Early Onset and Severe Disease Course by Autoantibody Profiling. Arthritis Rheumatol. 2015;67(9):2427–36.
22 Shiboski CH, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjogren’s syndrome: A consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis. 2017;76(1):9–16.
23 Spijkervet FK, et al. Parotid Gland Biopsy, the Alternative Way to Diagnose Sjogren Syndrome. Rheum Dis Clin North Am. 2016;42(3):485–99.
24 Barone F, et al. The value of histopathological examination of salivary gland biopsies in diagnosis, prognosis and treatment of Sjogren’s Syndrome. Swiss Med Wkly. 2015;145:p.w14168.
25 Carubbi F, et al. Is minor salivary gland biopsy more than a diagnostic tool in primary Sjogrens syndrome? Association between clinical, histopathological, and molecular features: a retrospective study. Semin Arthritis Rheum. 2014;44(3):314–24.
26 Delli K, et al. Towards personalised treatment in primary Sjogren’s syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment. Ann Rheum Dis. 2016;75(11):1933–8.
27 Baer AN, et al. The SSB-positive/SSA-negative antibody profile is not associated with key phenotypic features of Sjogren’s syndrome. Ann Rheum Dis. 2015;74(8):1557–61.